Pregnancy outcomes after maternal exposure to rituximab

Blood - Tập 117 - Trang 1499-1506 - 2011
Eliza F. Chakravarty1, Elaine R. Murray2, Ariella Kelman2, Pamela Farmer2
1Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
2Genentech Inc., South San Francisco, CA

Tóm tắt

Abstract Rituximab is a chimeric anti-CD20 monoclonal B cell–depleting antibody indicated for certain hematologic malignancies and active rheumatoid arthritis with inadequate response to tumor necrosis factor antagonists. Despite counseling to avoid pregnancy, women may inadvertently become pregnant during or after rituximab treatment. Using the rituximab global drug safety database, we identified 231 pregnancies associated with maternal rituximab exposure. Maternal indications included lymphoma, autoimmune cytopenias, and other autoimmune diseases. Most cases were confounded by concomitant use of potentially teratogenic medications and severe underlying disease. Of 153 pregnancies with known outcomes, 90 resulted in live births. Twenty-two infants were born prematurely; with one neonatal death at 6 weeks. Eleven neonates had hematologic abnormalities; none had corresponding infections. Four neonatal infections were reported (fever, bronchiolitis, cytomegalovirus hepatitis, and chorioamnionitis). Two congenital malformations were identified: clubfoot in one twin, and cardiac malformation in a singleton birth. One maternal death from pre-existing autoimmune thrombocytopenia occurred. Although few congenital malformations or neonatal infections were seen among exposed neonates, women should continue to be counseled to avoid pregnancy for ≤ 12 months after rituximab exposure; however, inadvertent pregnancy does occasionally occur. Practitioners are encouraged to report complete information to regulatory authorities for all pregnancies with suspected or known exposure to rituximab.

Tài liệu tham khảo

Rituxan [package insert]. Saji, 1999, Dynamics of immunoglobulins at the feto-maternal interface., Rev Reproduct, 4, 81, 10.1530/ror.0.0040081 Boothby, 2001, FDA labeling system for drugs in pregnancy., Ann Pharmacother, 35, 1485, 10.1345/aph.1A034 Kimby, 2004, Safety of rituximab therapy during the first trimester of pregnancy: a case history., Eur J Haematol, 72, 292, 10.1111/j.1600-0609.2004.00214.x Herold, 2001, Efficacy and safety of a combined rituximab chemotherapy during pregnancy [letter]., J Clin Oncol, 19, 3439 Decker, 2006, Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. [Published correction appears in Lancet Oncol. 2006;7:706]., Lancet Oncol, 7, 693, 10.1016/S1470-2045(06)70797-5 Friedrichs, 2006, The effects of rituximab treatment during pregnancy on a neonate., Haematologica, 91, 1426 Magloire, 2006, Burkitt's lymphoma of the ovary in pregnancy., Obstet Gynecol, 108, 743, 10.1097/01.AOG.0000189719.36625.8f Rey, 2009, Rituximab combined with chemotherapy for lymphoma during pregnancy., Leuk Res, 33, e8, 10.1016/j.leukres.2008.04.004 Scully, 2006, Successful management of pregnancy in women with a history of thrombotic thrombocytopenia purpura., Blood Coagul Fibrinolysis, 17, 459, 10.1097/01.mbc.0000240918.65306.20 Ojeda-Uribe, 2006, Administration of rituximab during the first trimester of pregnancy without consequences for the newborn., J Perinatol, 26, 252, 10.1038/sj.jp.7211481 Klink, 2008, Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development., Clin Dev Immunol, 2008, 2713363, 10.1155/2008/271363 Thurlings, 2010, Clinical responses, pharmacokinetics, development of human anti-chimeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis., Ann Rheum Dis, 69, 409, 10.1136/ard.2009.109041 Lu, 2009, A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients., Arthritis Rheum, 61, 482, 10.1002/art.24341 Bruzzese, 2009, Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)., Reumatismo, 61, 306 Finer, 2006, Disparities in rates of unintended pregnancy in the United States, 1994 and 2001., Perspect Sex Reprod Health, 38, 90, 10.1363/3809006 Ton, 2009, Rituximab and pregnancy: safe before conception? A case report and review of the literature [abstract]., Ann Rheum Dis, 68 Muglia, 2010, The enigma of spontaneous preterm birth., N Engl J Med, 362, 529, 10.1056/NEJMra0904308 Golding, 2007, Rheumatoid arthritis and reproduction., Rheum Dis Clin N Am, 33, 319, 10.1016/j.rdc.2007.01.001 Clowse, 2007, Lupus activity in pregnancy., Rheum Dis Clin N Am, 33, 237, 10.1016/j.rdc.2007.01.002 Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities. Accessed February 28, 2010 http://www.cdc.gov/ncbddd/bd/faq1.htm#chanceofBD Ostensen, 2006, Anti-inflammatory and immunosuppressive drugs and reproduction., Arthritis Res Ther, 8, 209, 10.1186/ar1957 Cardonick, 2004, Use of chemotherapy during human pregnancy., Lancet Oncol, 5, 283, 10.1016/S1470-2045(04)01466-4 Pereg, 2007, The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy., Haematologica, 92, 1230, 10.3324/haematol.11097 de Man, 2009, Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weights: results of a national prospective study., Arthritis Rheum, 60, 3196, 10.1002/art.24914 D'Angelo, 2009, Thrombotic microangiopathy in pregnancy., Thrombosis Res, 123, S56, 10.1016/S0049-3848(09)70012-X Mulvihill, 1987, Pregnancy outcome in cancer patients. Experience in a large cooperative group., Cancer, 60, 1143, 10.1002/1097-0142(19870901)60:5<1143::AID-CNCR2820600537>3.0.CO;2-E Mecacci, 2007, The impact of autoimmune disorders and adverse pregnancy outcome., Semin Perinatol, 31, 223, 10.1053/j.semperi.2007.05.005 Webert, 2003, A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenia purpura., Blood, 102, 4306, 10.1182/blood-2002-10-3317 FDA Medwatch Online Voluntary Reporting Form (3500).
Thông tin
Thông tin xuất bản

Blood

Tập 117

1499-1506

Thông tin tác giả